Apellis Pharmaceuticals Inc (APLS)

$27.97 +0.35 (1.27%)
Market Cap 3.53B
Revenue (ttm) 781.37M
Net Income (ttm) -197.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25.32%
Debt to Equity Ratio 2.31
Volume 1,823,700
Avg Vol 2,413,742
Day's Range N/A - N/A
Shares Out 126.29M
Stochastic %K 82%
Beta 0.78
Analysts Strong Sell
Price Target $37.10

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 977 5700
Website: apellis.com
Address:
100 Fifth Avenue, Waltham, United States
TradeForager
TradeForager Aug. 23 at 5:47 AM
$APLS Apellis Pharmaceuticals faces safety concerns with its complement inhibitor but has approved products
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 22 at 2:59 PM
$APLS rate cuts pushes this back over $30
0 · Reply
ThatsNoMoon
ThatsNoMoon Aug. 22 at 2:13 PM
$APLS I can’t believe sentiment is still bearish 🤷🏻‍♂️
0 · Reply
Georgeson
Georgeson Aug. 21 at 8:01 PM
$APLS Wow, beautiful strong finish for a change! Still too early to tell but something brewing??
0 · Reply
buylowandwait
buylowandwait Aug. 21 at 5:51 PM
$APLS Pls keep in mind GA market is only fractional penetrated at this stage (<15%), once GA market resumes growth, the price need to go a lot higher. (look at the price a couple of years back). Combined with the wonder new drug for C3G/IC-MPGN, we've got big runway ahead...
0 · Reply
Shaka_MT
Shaka_MT Aug. 20 at 8:17 PM
$APLS looks like 1 idiot sells thousands of apls everyday in last five minutes before market close
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 20 at 3:18 PM
$APLS the MM has stalled this-he wants to see if they are telling stories on the % of scripts next Quarter; hopefully they have exhausted all the free samples laying around.
0 · Reply
diegosan21
diegosan21 Aug. 19 at 1:41 PM
sold my $SRPT and $APLS at a 100% profit, will take them back later, GL to the longs
1 · Reply
Georgeson
Georgeson Aug. 18 at 6:35 PM
$APLS Strong push in last 90 min to push it above $28??
0 · Reply
G101SPM
G101SPM Aug. 18 at 6:31 PM
$APLS $27.87 bid. SELL/TAKE PROFIT ON ENTIRE POSITION. DAC (8) $25.465 / last $19.56 (6.6.25).
0 · Reply
Latest News on APLS
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Aug 14, 2025, 12:12 PM EDT - 9 days ago

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

Aug 2, 2025, 4:23 AM EDT - 22 days ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

Apellis Pharmaceuticals: The Picture Becomes Clearer

Aug 1, 2025, 2:29 PM EDT - 22 days ago

Apellis Pharmaceuticals: The Picture Becomes Clearer

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:05 AM EDT - 24 days ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

Jul 29, 2025, 12:12 PM EDT - 25 days ago

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Jul 28, 2025, 7:19 PM EDT - 26 days ago

FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 4 weeks ago

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Jul 15, 2025, 7:00 AM EDT - 5 weeks ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Jul 1, 2025, 7:35 AM EDT - 7 weeks ago

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Jul 1, 2025, 7:00 AM EDT - 7 weeks ago

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Jun 6, 2025, 9:15 AM EDT - 2 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 2 months ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Apellis Pharmaceuticals: Have Some Patience

May 20, 2025, 9:28 AM EDT - 3 months ago

Apellis Pharmaceuticals: Have Some Patience

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 1:18 PM EDT - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 3 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

May 6, 2025, 7:00 AM EDT - 3 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 4 months ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 21, 2025, 7:00 AM EDT - 4 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 2:11 PM EDT - 5 months ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:06 PM EST - 6 months ago

Apellis Pharmaceuticals: A Mixed Bag

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 5, 2025, 2:04 PM EST - 6 months ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Mar 2, 2025, 2:08 AM EST - 6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 7:05 AM EST - 6 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 7:00 AM EST - 6 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Feb 20, 2025, 2:00 AM EST - 6 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 14, 2025, 7:00 AM EST - 6 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2025, 4:05 PM EST - 7 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Jan 27, 2025, 4:00 PM EST - 7 months ago

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect

Jan 21, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out

Jan 20, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation

Jan 19, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 7 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation

Jan 16, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 15, 2025, 10:00 AM EST - 7 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Jan 14, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Jan 13, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 9:00 AM EST - 7 months ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect

Jan 10, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 8 months ago

Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out

Jan 6, 2025, 12:30 PM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 8 months ago

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 3:14 PM EST - 10 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 7:05 AM EST - 10 months ago

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Oct 26, 2024, 2:00 PM EDT - 10 months ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

Oct 16, 2024, 2:56 PM EDT - 11 months ago

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

TradeForager
TradeForager Aug. 23 at 5:47 AM
$APLS Apellis Pharmaceuticals faces safety concerns with its complement inhibitor but has approved products
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 22 at 2:59 PM
$APLS rate cuts pushes this back over $30
0 · Reply
ThatsNoMoon
ThatsNoMoon Aug. 22 at 2:13 PM
$APLS I can’t believe sentiment is still bearish 🤷🏻‍♂️
0 · Reply
Georgeson
Georgeson Aug. 21 at 8:01 PM
$APLS Wow, beautiful strong finish for a change! Still too early to tell but something brewing??
0 · Reply
buylowandwait
buylowandwait Aug. 21 at 5:51 PM
$APLS Pls keep in mind GA market is only fractional penetrated at this stage (<15%), once GA market resumes growth, the price need to go a lot higher. (look at the price a couple of years back). Combined with the wonder new drug for C3G/IC-MPGN, we've got big runway ahead...
0 · Reply
Shaka_MT
Shaka_MT Aug. 20 at 8:17 PM
$APLS looks like 1 idiot sells thousands of apls everyday in last five minutes before market close
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 20 at 3:18 PM
$APLS the MM has stalled this-he wants to see if they are telling stories on the % of scripts next Quarter; hopefully they have exhausted all the free samples laying around.
0 · Reply
diegosan21
diegosan21 Aug. 19 at 1:41 PM
sold my $SRPT and $APLS at a 100% profit, will take them back later, GL to the longs
1 · Reply
Georgeson
Georgeson Aug. 18 at 6:35 PM
$APLS Strong push in last 90 min to push it above $28??
0 · Reply
G101SPM
G101SPM Aug. 18 at 6:31 PM
$APLS $27.87 bid. SELL/TAKE PROFIT ON ENTIRE POSITION. DAC (8) $25.465 / last $19.56 (6.6.25).
0 · Reply
ThatsNoMoon
ThatsNoMoon Aug. 18 at 12:17 PM
$APLS Wow, 21% short interest. I feel like recent earnings and EMPAVELI label expansion largely derisked the name, at least in the short to medium term. But I’m long and obviously biased 🤷🏻‍♂️
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 18 at 4:06 AM
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary $APLS https://stocktwits.com/news/equity/markets/apellis-short-bets-edge-higher-as-stock-jumps-45-since-late-july-q2-report-retail-traders-stay-wary/chsaydQRdQB
0 · Reply
The_Fact_ster
The_Fact_ster Aug. 16 at 2:16 PM
$APLS last few weeks have been long overdue, CRAZY though that we are still obviously undervalued by so much - we were at ~45 before final EMA rejection roughly 11 months ago. IMO that is bare minimum reasonable price for this guy.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 16 at 1:41 AM
$APLS
0 · Reply
BB_88_
BB_88_ Aug. 15 at 10:51 PM
$APLS she got legs watched this go to 80 down to 20 then right back to 70s now back to 16
1 · Reply
diegosan21
diegosan21 Aug. 15 at 8:21 PM
Strong week 🦾🦾🚀 $SRPT $APLS $AAL $ARVN
0 · Reply
theflynews
theflynews Aug. 15 at 7:49 PM
Short Report: Kohls, Krispy Kreme shorts cover as meme stock fever breaks - $APLS - https://thefly.com/permalinks/entry.php/APLSid4184526?1
0 · Reply
Spanner1968
Spanner1968 Aug. 15 at 5:53 PM
$APLS 50% profit makes the 39% loss palatable!
1 · Reply
Georgeson
Georgeson Aug. 15 at 5:27 PM
$APLS Maybe VP at FDA is a changed man. PGEN up 75% today on FDA approval. https://www.fiercepharma.com/pharma/precigen-scores-fda-nod-first-ever-treatment-hpv-related-disorder
0 · Reply
Georgeson
Georgeson Aug. 15 at 4:57 PM
$APLS Wow biotechs are in fashion again.
0 · Reply
diegosan21
diegosan21 Aug. 15 at 4:44 PM
$SRPT $APLS $ARVN looking great today
0 · Reply
Georgeson
Georgeson Aug. 15 at 3:20 PM
$APLS KURA ceo just filed that he bought $300K of KURA in open market. KURA is up about 14% today so far. Imagine IF Cedric bought some shares in the open market.
0 · Reply